An experimental drug called retatrutide helped participants in a large trial lose an average of 28% of their body weight after 80 weeks. Pharmaceutical company Eli Lilly released the results this Thursday. The data indicate a superior effect compared to other obesity medications already available on the market.
The trial included thousands of obese or overweight adults who received diet and physical activity guidance throughout the period. Entre the heaviest patients, the reduction approached the results observed in gastric bypass surgeries. Alguns volunteers reported losing so much weight that they stopped treatment because they considered the loss excessive.
Como retatrutide works in the body
The medication is a triple agonist that activates GIP, GLP-1 and glucagon receptors simultaneously. Essa combination influences appetite, energy expenditure and metabolism more broadly than currently available dual agonists. Administration occurs once a week, by subcutaneous injection.
The highest dose tested was 12 milligrams per week. Pesquisadores noted that:
- Perda average 28% of initial weight in the treated group
- Comparação with placebo showed a significant and significant difference
- Período 80-week study was longer than many previous trials
- Resultados not yet published in a peer-reviewed scientific journal
Efeitos side effects and treatment interruption
Náusea, diarrhea, vomiting and constipation appeared more frequently in the group that used retatrutide. At high doses, these gastrointestinal symptoms led some volunteers to withdraw from the trial. The discontinuation rate due to adverse events varied depending on the participants’ initial body mass index.
The safety profile is similar to that of other medications in the same therapeutic class. Médicos reinforce that treatment requires continuous professional monitoring to assess tolerance and adjust doses when necessary.
Comparação with surgical procedures
In subgroups with severe obesity, weight reduction reached levels close to those of bariatric surgery. Essa equivalence is unprecedented among currently available pharmacological treatments. The drug also improved metabolic markers such as blood pressure, cholesterol and inflammation in several patients.
Perdas above 20% of body weight already transforms the clinical management of the disease. Especialistas follow development because obesity affects hundreds of millions of people worldwide. Retatrutide can further expand these therapeutic possibilities.
Próximos steps and regulatory approval
Eli Lilly intends to present complete data at medical congresses and submit the medicine to international regulatory agencies. Outros phase 3 trials of the TRIUMPH program are ongoing and should bring results throughout 2026. Retatrutide is not yet approved for commercial use in any jurisdiction.
Qualquer current application occurs only in research contexts duly approved by ethics committees. The results released this week represent an important milestone in the history of the pharmacological treatment of obesity, although the lack of publication in peer-reviewed journals allows only preliminary analysis of the data.
Comparação with medicines now available
Medicamentos like semaglutide and tirzepatide already offer significant losses in their respective clinical trials. Retatrutide appears as the most potent to date in the data released by the pharmaceutical company. The difference arises mainly in the magnitude of weight reduction and the maintenance of the effect over the prolonged period of treatment.
Mean Perda greater than 20% has been observed in several previous studies with dual agonists. Melhora in associated conditions such as knee osteoarthritis has also been recorded. Continuação of loss without evident plateau occurred in many cases during the 80 weeks.
Cost and future accessibility Desafios
Cost and accessibility are still unknowns that concern public health managers. Especialistas expects the arrival of new pharmacological options to increase competition in the market and possibly reduce prices in the future. The need for gradual dose titration to reduce initial discomfort also requires consideration in patient access.